PharmExec articleshttps://www.pharmexec.com/newsPharmExec articles© 2026 MJH Life Sciences™ and PharmExec. All rights reserved.Sun, 31 May 2026 05:00:38 +00005en-us14447https://www.pharmexec.com/newshttps://www.pharmexec.com/logo.webphttps://www.pharmexec.com/view/daily-who-identifies-priority-treatment-candidates-ebolahttps://www.pharmexec.com/view/daily-who-identifies-priority-treatment-candidates-ebola<![CDATA[In today’s Pharmaceutical Executive Daily, Harpreet Singh discusses the evolving regulatory landscape for biopharma, the World Health Organization identifies three priority treatment candidates for the Bundibugyo strain of Ebola virus disease, and this week’s pharma roundup highlights new findings on Mounjaro and long COVID-related immune system changes.]]>Fri, 29 May 2026 17:36:04 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/who-prioritizes-three-treatments-bundibugyo-ebolahttps://www.pharmexec.com/view/who-prioritizes-three-treatments-bundibugyo-ebola<![CDATA[WHO identifies experimental therapies from Mapp Biopharmaceutical, Regeneron, and Gilead as leading candidates for the Bundibugyo strain of Ebola virus disease, as the agency pushes for urgent clinical trials amid a growing outbreak.]]>Fri, 29 May 2026 14:08:23 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/pharma-roundup-mounjaro-advantages-type-2-diabetes-immune-system-linked-long-covid-symptomshttps://www.pharmexec.com/view/pharma-roundup-mounjaro-advantages-type-2-diabetes-immune-system-linked-long-covid-symptoms<![CDATA[Research published this week highlights tirzepatide outperforming other GLP-1 therapies in early type 2 diabetes treatment while separate studies identified autoantibodies as a likely biological driver behind persistent neurological symptoms in some long Covid patients.]]>Fri, 29 May 2026 13:45:23 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/fda-timeline-dtc-prescription-drug-ad-oversighthttps://www.pharmexec.com/view/fda-timeline-dtc-prescription-drug-ad-oversight<![CDATA[Former chief counsel for FDA Dan Troy explains why there is no firm timeline for regulatory reform or update at FDA for DTC pharma advertisements.]]>Fri, 29 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-cvs-health-offer-zepbound-and-foundayohttps://www.pharmexec.com/view/daily-cvs-health-offer-zepbound-and-foundayo<![CDATA[In today’s Pharmaceutical Executive Daily, an FDA advisory committee weighs recommendations for the composition of the 2026–2027 Covid-19 vaccines, CVS Health restores coverage for Eli Lilly’s Zepbound while adding the company’s newly approved obesity pill Foundayo, and experts discuss how treatment expectations are evolving in lupus care.]]>Thu, 28 May 2026 18:43:11 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/cvs-restores-coverage-lilly-zepbound-adds-foundayohttps://www.pharmexec.com/view/cvs-restores-coverage-lilly-zepbound-adds-foundayo<![CDATA[CVS Health is restoring coverage of Eli Lilly’s Zepbound and adding oral obesity drug Foundayo to its formulary, signaling shifting payer dynamics as lower-cost GLP-1 therapies expand access for patients. ]]>Thu, 28 May 2026 14:30:13 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/fda-advisory-panel-vote-composition-covid-19-vaccines-2026-2027https://www.pharmexec.com/view/fda-advisory-panel-vote-composition-covid-19-vaccines-2026-2027<![CDATA[FDA advisors are set to meet this week to determine whether Covid-19 vaccines should be updated to target the emerging XFG variant, a decision that could shape the composition of the 2026–2027 immunization season amid ongoing viral evolution.]]>Thu, 28 May 2026 14:07:05 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/impact-strict-oversight-dtc-prescription-drug-adshttps://www.pharmexec.com/view/impact-strict-oversight-dtc-prescription-drug-ads<![CDATA[Dan Troy, former FDA chief counsel, explains limits on what regulations FDA can put on DTC advertisements.]]>Thu, 28 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/changing-standard-care-lupus-treatment-albert-t-royhttps://www.pharmexec.com/view/changing-standard-care-lupus-treatment-albert-t-roy<![CDATA[The Lupus Research Alliance’s CEO and president discusses how recent treatment breakthroughs are changing the patient experience in Lupus treatment.]]>Thu, 28 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/evolving-biopharma-regulatory-landscape-qa-harpreet-singh-mdhttps://www.pharmexec.com/view/evolving-biopharma-regulatory-landscape-qa-harpreet-singh-md<![CDATA[Harpreet Singh, former FDA Oncology Division Director and current chief medical officer at Precision for Medicine notes how evolving FDA review standards, expedited approval programs, and emerging AI tools are reshaping the regulatory landscape for biopharma companies.]]>Thu, 28 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/push-fda-tighten-oversight-dtc-prescription-drug-adshttps://www.pharmexec.com/view/push-fda-tighten-oversight-dtc-prescription-drug-ads<![CDATA[Former FDA chief counsel Dan Troy discusses the motivation behind potential DTC pharma ad bans.]]>Wed, 27 May 2026 18:05:03 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/how-ai-improve-fda-internal-processhttps://www.pharmexec.com/view/how-ai-improve-fda-internal-process<![CDATA[Harpreet Singh, MD, notes that FDA’s internal AI system could improve efficiency in drug review by helping reviewers aggregate and synthesize complex data.]]>Wed, 27 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/ending-relay-race-non-opioid-breakthroughhttps://www.pharmexec.com/view/ending-relay-race-non-opioid-breakthrough<![CDATA[A fragmented approach to drug discovery created structural inefficiencies that drive up R&amp;D costs.]]>Wed, 27 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-fda-approves-hepcludexhttps://www.pharmexec.com/view/daily-fda-approves-hepcludex<![CDATA[In today’s Pharmaceutical Executive Daily, Eli Lilly announces three acquisitions totaling roughly $3 billion, the FDA approves Hepcludex as the first treatment for chronic hepatitis delta virus infection in the United States, and biotech finance leaders reflect on the lessons learned from navigating two decades of volatile markets.]]>Tue, 26 May 2026 18:50:51 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/fda-approves-hepcludex-first-approved-treatment-chronic-hepatitis-delta-virushttps://www.pharmexec.com/view/fda-approves-hepcludex-first-approved-treatment-chronic-hepatitis-delta-virus<![CDATA[FDA approves Gilead’s Hepcludex as the first treatment for chronic hepatitis delta virus in the U.S., marking a major milestone for a severe liver disease with limited therapeutic options.]]>Tue, 26 May 2026 14:52:30 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/eli-lilly-three-acquisitions-totaling-3-billionhttps://www.pharmexec.com/view/eli-lilly-three-acquisitions-totaling-3-billion<![CDATA[Eli Lilly enters three separate acquisitions totaling $3.83 billion in a push into vaccines and infectious diseases, signaling a strategic expansion into prevention-focused medicines. ]]>Tue, 26 May 2026 14:00:10 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/do-you-think-cnpv-program-delivered-promises-https://www.pharmexec.com/view/do-you-think-cnpv-program-delivered-promises-<![CDATA[Harpreet Singh, MD, touches on how the Commissioner’s National Priority Voucher program is accelerating regulatory review timelines without fundamentally changing how pivotal trials are designed.]]>Tue, 26 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/implications-rising-glp-market-kevin-dondarskihttps://www.pharmexec.com/view/implications-rising-glp-market-kevin-dondarski<![CDATA[The Deloitte Consulting partner discusses how GLP-1s are becoming key value drivers and driving R&amp;D focus during a period of market concentration.]]>Tue, 26 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/navigating-turbulent-markets-two-decades-biotech-finance-taught-building-companies-lasthttps://www.pharmexec.com/view/navigating-turbulent-markets-two-decades-biotech-finance-taught-building-companies-last<![CDATA[Drawing on nearly two decades in biotech finance,Troy Ignelzi outlines why operational discipline, strategic storytelling, and long-term conviction have become essential survival tools in an increasingly unforgiving life sciences market.]]>Tue, 26 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/reputation-stewardship-driving-stakeholder-action-business-momentumhttps://www.pharmexec.com/view/reputation-stewardship-driving-stakeholder-action-business-momentum<![CDATA[Reputation is one of the factors that influences whether the people who matter most to your business decide whether to move with you.]]>Tue, 26 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/kinds-disruption-glp-expected-facehttps://www.pharmexec.com/view/kinds-disruption-glp-expected-face<![CDATA[Kevin Dondarskit of Deloitte Consulting discusses the risks that drug makers face if they decide to put too much focus on an area where they may lack expertise, such as the emerging GLP-1 market.]]>Mon, 25 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-fda-approves-datrowayhttps://www.pharmexec.com/view/daily-fda-approves-datroway<![CDATA[In today’s Pharmaceutical Executive Daily, the FDA approves Datroway for certain patients with metastatic triple-negative breast cancer, leadership changes continue at the National Institutes of Health with the departure of a top infectious disease institute director, and industry experts discuss how real-time data is reshaping biotech decision-making and development strategy.]]>Fri, 22 May 2026 17:54:50 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/fda-approves-datroway-metastatic-triple-negative-breast-cancer-pd-1-pd-l1-inhibitor-candidateshttps://www.pharmexec.com/view/fda-approves-datroway-metastatic-triple-negative-breast-cancer-pd-1-pd-l1-inhibitor-candidates<![CDATA[FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for first-line metastatic triple-negative breast cancer, expanding treatment options for patients ineligible for PD-1/PD-L1 inhibitor therapy.]]>Fri, 22 May 2026 17:26:15 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/director-of-nih-infectious-disease-institute-steps-downhttps://www.pharmexec.com/view/director-of-nih-infectious-disease-institute-steps-down<![CDATA[Jeffrey Taubenberger’s departure was announced by Senator Baldwin during a congressional hearing.]]>Fri, 22 May 2026 14:15:23 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/you-can-build-ai-in-house-but-should-youhttps://www.pharmexec.com/view/you-can-build-ai-in-house-but-should-you<![CDATA[]]>Fri, 22 May 2026 12:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/ai-doesn-t-drive-better-outcomes-better-systems-dohttps://www.pharmexec.com/view/ai-doesn-t-drive-better-outcomes-better-systems-do<![CDATA[AI models are improving—but outcomes aren’t. This POV reveals why real-world performance breaks down across pharma—and what it takes to fix it, from end-to-end system design to embedded human judgment. See how leading organizations are turning AI from isolated outputs to scalable, trusted decision making.]]>Fri, 22 May 2026 12:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/the-shift-pharma-can-t-afford-to-miss-from-ai-experimentation-to-executionhttps://www.pharmexec.com/view/the-shift-pharma-can-t-afford-to-miss-from-ai-experimentation-to-execution<![CDATA[]]>Fri, 22 May 2026 12:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/biotech-industry-relationship-real-time-data-dr-richard-grahamhttps://www.pharmexec.com/view/biotech-industry-relationship-real-time-data-dr-richard-graham<![CDATA[]]>Fri, 22 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/modern-communication-between-fda-biotech-investors-david-creanhttps://www.pharmexec.com/view/modern-communication-between-fda-biotech-investors-david-crean<![CDATA[MedicNova’s chief business officer details how changes at FDA are causing tension with the industry and investors, who are finding themselves less confident in the regulatory process.]]>Fri, 22 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/driving-concentration-blockbuster-drugshttps://www.pharmexec.com/view/driving-concentration-blockbuster-drugs<![CDATA[Kevin Dondarskit of Deloitte Consulting discusses how pharma companies are focusing on high-value assets that serve large patient populations.]]>Fri, 22 May 2026 10:00:00 GMTPharmExecusPharmExec Articles